The expression of transglutaminase 2 is increased in SSc and regulates fibroblast activation in three-dimensional full thickness skin models.

We provide first evidence that inhibition of TG2 might be a potential antifibrotic approach in SSc. Our findings have translational potential as anti-TG2 antibodies are currently evaluated in a phase 2 clinical trial in chronic allograft injury and would thus be available for clinical studies in SSc (NCT04335578). This article is protected by copyright. All rights reserved.